Biocardia, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Biocardia, Inc. (BCDA) on July 2, 2025, reporting events occurring on June 30, 2025. The company is a Delaware corporation incorporated in 2025, with principal executive offices in Sunnyvale, California. The filing details a private placement of equity securities.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data relates to the capital raise:
- Gross Proceeds: Approximately $570,000 (before transaction expenses).
- Securities Issued: 274,696 shares of common stock and warrants to purchase an equal number of shares.
- Purchase Price: $2.075 per unit (share plus warrant).
- Warrant Exercise Price: $1.95 per share.
- Warrant Expiration: June 30, 2030, or earlier upon approval of the CardiAMP Cell Therapy System by the Japanese Pharmaceuticals and Medical Devices Agency.
Material Changes
The material change reported is the completion of a private placement on June 30, 2025. This transaction resulted in the issuance of new common stock and warrants to qualified institutional buyers, institutional accredited investors, and certain company insiders. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Management Commentary
Use of Proceeds: The company intends to use the net proceeds for general corporate purposes.
Registration Rights: The company agreed to file a registration statement with the SEC by July 10, 2025, to allow for the resale of the shares and issuable shares. The company will use commercially reasonable efforts to keep this statement effective until all registrable securities are sold, Rule 144 restrictions are lifted, or June 30, 2027, whichever occurs first.
Risks and Contingencies: The securities were issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933. The filing notes that the warrant expiration is contingent on regulatory approval in Japan for the CardiAMP Cell Therapy System.
Investor Verification Checklist
- Verify the final closing amount and any transaction expenses deducted from the gross proceeds of $570,000.
- Confirm the filing date and effectiveness of the Registration Statement required by July 10, 2025.
- Review the full text of the Securities Purchase and Registration Rights Agreement (Exhibit 4.1) for specific adjustment mechanisms on the warrant exercise price.
- Monitor the status of the Japanese Pharmaceuticals and Medical Devices Agency approval for the CardiAMP Cell Therapy System, as this impacts warrant expiration.
- Check subsequent filings for the actual cash balance impact of this transaction on the company's liquidity.